BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates

BACKGROUND: The marked increase in mis-use of prescription opioids has greatly affected our society. One potential solution is to develop improved analgesics which have agonist action at both mu opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors. BU10038 is a recently identified...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Anaesth
Autors principals: Kiguchi, Norikazu, Ding, Huiping, Cami-Kobeci, Gerta, Sukhtankar, Devki D., Czoty, Paul W., DeLoid, Heather B., Hsu, Fang-Chi, Toll, Lawrence, Husbands, Stephen M., Ko, Mei-Chuan
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6676776/
https://ncbi.nlm.nih.gov/pubmed/30916003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bja.2018.10.065
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars